TLP
RXRX icon

Tri Locum Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Tri Locum Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,471
Closed -$172K – 50
2023
Q3 		$172K Buy
+22,471
New +$224K 0.06% 51

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Tri Locum Partners's RXRX Position: Q4 2023 in Review

Tri Locum Partners sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 22,471 shares — an estimated $172K sold.

Tri Locum Partners first reported a position in RXRX in Q3 2023 and held it in 1 quarter. The position peaked at $172K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • Tri Locum Partners reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 22,471 Recursion Pharmaceuticals shares in Q4 2023, an estimated $172K.
  • Tri Locum Partners first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Tri Locum Partners's Recursion Pharmaceuticals position peaked at $172K in Q3 2023.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.